These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8391242)

  • 21. Prognostic impact of Deoxyribonucleic acid (DNA) image analysis cytometry and immunohistochemical expression of Ki67 in surgically resected non-small cell lung cancers.
    Maounis NF; Chorti M; Apostolakis E; Ellina E; Blana A; Aggelidou M; Dritsas I; Markidou S
    Cancer Detect Prev; 2006; 30(6):507-14. PubMed ID: 17113721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Flow cytometric analysis in non-small-cell bronchial carcinoma and its prognostic significance].
    Liewald F; Sunder-Plassmann L; Valet G; Wulf G; Weiss M; Schildberg FW
    Chirurg; 1992 Mar; 63(3):205-10. PubMed ID: 1313755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laminin and cathepsin B as prognostic factors in stage I non-small cell lung cancer: are they useful?
    Mori M; Kohli A; Baker SP; Savas L; Fraire AE
    Mod Pathol; 1997 Jun; 10(6):572-7. PubMed ID: 9195574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers.
    Simony J; Pujol JL; Radal M; Ursule E; Michel FB; Pujol H
    Cancer Res; 1990 Jul; 50(14):4382-7. PubMed ID: 2163748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
    Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
    Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis.
    Xu HJ; Cagle PT; Hu SX; Li J; Benedict WF
    Clin Cancer Res; 1996 Jul; 2(7):1169-76. PubMed ID: 9816284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology.
    Maddau C; Confortini M; Bisanzi S; Janni A; Montinaro F; Paci E; Pontenani G; Rulli P; Salani A; Zappa M; Benvenuti A; Carozzi FM
    Am J Clin Pathol; 2006 Mar; 125(3):425-31. PubMed ID: 16613347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do bone marrow isolated tumor cells influence long-term survival of non-small cell lung cancer?
    Ruffato A; Mattioli S; Pileri S; Daddi N; D'Ovidio F; Pilotti V; Tazzari P
    Eur J Cardiothorac Surg; 2009 Mar; 35(3):463-8. PubMed ID: 19150243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
    Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer.
    Bennett WP; el-Deiry WS; Rush WL; Guinee DG; Freedman AN; Caporaso NE; Welsh JA; Jones RT; Borkowski A; Travis WD; Fleming MV; Trastek V; Pairolero PC; Tazelaar HD; Midthun D; Jett JR; Liotta LA; Harris CC
    Clin Cancer Res; 1998 Jun; 4(6):1499-506. PubMed ID: 9626468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer.
    Tan DF; Li Q; Rammath N; Beck A; Wiseman S; Anderson T; al-Salameh A; Brooks J; Bepler G
    Anticancer Res; 2003; 23(2C):1665-72. PubMed ID: 12820438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas.
    Mørkve O; Laerum OD
    Cytometry; 1991; 12(5):438-44. PubMed ID: 1935458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.
    Graziano SL; Tatum AH; Gonchoroff NJ; Newman NB; Kohman LJ
    Clin Cancer Res; 1997 Jan; 3(1):87-93. PubMed ID: 9815542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers.
    Nishio M; Koshikawa T; Yatabe Y; Kuroishi T; Suyama M; Nagatake M; Sugiura T; Ariyoshi Y; Mitsudomi T; Takahashi T
    Clin Cancer Res; 1997 Jul; 3(7):1051-8. PubMed ID: 9815783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Flow cytometric analysis of the DNA content of resected non-small cell lung cancer with reference to long-term follow-up].
    Nagai S; Chiba W; Ikeda S; Matsumoto H; Fujimoto T; Ishida H; Wazawa H; Hanawa T; Yamashita N; Yasuda Y; Matsubara Y; Hatakenaka R; Funatsu T
    Gan To Kagaku Ryoho; 1996 Jun; 23 Suppl 2():130-4. PubMed ID: 8678555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study of prognostic factors in patients with stage I non-small cell lung cancer].
    Jiang ZQ; Jiang GL; Shi DR; Zhang RX; Fu XL; Qian H
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):364-8. PubMed ID: 15312349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.